Rising interest in medical marijuana has prompted research into its phytocannabinoid constituents, particularly Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD). Coadministration of CBD with THC has been shown to modulate a number of THC's effects, including its negative stimulus properties (e.g., anxiety, paranoia, psychosis) in a clinical setting. The present series of experiments extended...
In pre-clinical models of marijuana abuse, there is relatively limited evidence of delta-9-tetrahydrocannabinol's (THC) rewarding effects, as indexed by its general inability to induce a place preference. One explanation for this failure is that its rewarding effects are masked by its concurrently occurring aversive properties. Consistent with this explanation, THC pre-exposure, which...
Rationale Δ 9 ‐Tetrahydrocannabinol (THC) produces both aversive and rewarding effects in animal models. Given that the balance between a drug's affective properties is thought to underlie its abuse potential, it is important to consider these properties of THC and how they (and their balance) are impacted by various factors. In this context, previous studies have examined the effect of THC...